Table 1.
Characteristics of study participants
| Description | Major Beta Thalassemia | Acutely ill | Acute Lymphoblastic Leukaemia | Haemophilia | All subjects |
|---|---|---|---|---|---|
| Number of patients | |||||
| tbaseline | 68 | 124 | 40 | 54 | 286 |
| tretest | 66 | 94 | 39 | 44 | 243 |
| tfollowup | 65 | 90 | 28 | 46 | 229 |
| % female | 54.4 | 43.5 | 42.5 | 1.9 | 38.1 |
| Mean age (SD) | 11.6 (2.4) | 10.9 (2.3) | 10.9 (2.5) | 11.9 (2.6) | 11.2 (2.4) |
| Age at first diagnosis | 4.5 (3.2) | NA | 7.6 (3.7) | 3 (3) | NA |
| Patients eligible for analysis* | |||||
| tretest | 19 | 8 | 6 | 11 | 44 |
| tfollowup | 62 | 88 | 26 | 43 | 219 |
| Hospital visit | |||||
| Every week | – | 27 | |||
| Every 2 weeks | 35 | NA | NA | 20 | NA |
| Every 3 weeks | 24 | NA | |||
| Every month | 8 | 6 | |||
| Other | 1 | – | |||
*Patients eligible for analysis are the patients who report expected health status at retest (indicate no change) and responsiveness (improved). The large difference between eligible patients for retest and follow-up was because a small proportion of patients reported no changes in their health during the retest assessment